Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18258631 | 1.00 | GPR84 (0.48) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL5524539 | 0.98 | NPSR1 (0.47) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL18258587 | 0.93 | NPSR1 (0.49) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL18258589 | 0.93 | NPSR1 (0.49) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL18258632 | 0.85 | NPSR1 (0.52) | MAPTNPSR1HSD17B10PPARG | |
| SCHEMBL5512388 | 0.85 | NPSR1 (0.52) | MAPTNPSR1HSD17B10PPARG | |
| SCHEMBL11536801 | 0.82 | HSD17B10 (0.46) | FFAR1MAPTNPSR1HSD17B10FFAR4 | |
| SCHEMBL11534759 | 0.82 | HSD17B10 (0.46) | FFAR1MAPTNPSR1HSD17B10FFAR4 | |
| SCHEMBL11536585 | 0.82 | HSD17B10 (0.46) | FFAR1MAPTNPSR1HSD17B10FFAR4 | |
| SCHEMBL11537659 | 0.82 | HSD17B10 (0.46) | FFAR1MAPTNPSR1HSD17B10FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190069527-A1 | MOUSE MODEL OF RETINAL DEGENERATION | CLEVELAND CLINIC FOUNDATION | 2019-03-07 | — | — | US | disclosed |
| US-20180160660-A1 | MOUSE MODEL OF RETINAL DEGENERATION | CLEVELAND CLINIC FOUNDATION | 2018-06-14 | — | — | US | disclosed |
| US-9796640-B2 | Method for producing optically active carboxylic acid ester | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20170105394-A1 | MOUSE MODEL OF RETINAL DEGENERATION | CLEVELAND CLINIC FOUNDATION | 2017-04-20 | — | — | US | disclosed |
| US-20170008820-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2017-01-12 | — | — | US | disclosed |
| EP-3098217-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | Tokyo University of Science Foundation (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20160242397-A1 | MOUSE MODEL OF RETINAL DEGENERATION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-08-25 | — | — | US | disclosed |
| US-20140182004-A1 | MOUSE MODEL OF RETINAL DEGENERATION | THE CLEVELAND CLINIC FOUNDATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-8664470-B2 | Mouse model of retinal degeneration | THE CLEVELAND CLINIC FOUNDATION (US) | 2014-03-04 | — | — | US | disclosed |
| US-20090155243-A1 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008089487-A2 | CARBOXYETHYLPYRROLE COMPOUNDS AND METHODS OF THEIR PRODUCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089485-A2 | CARBOXYETHYLPYRROLE COMPOUNDS AND METHODS OF THEIR PRODUCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007127151-A2 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008820-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | ADH1A, ALDH1A2, ADH1C | GPR84 948/4885FFAR1 68/4885MAPT 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.